natgillin/translations-raw huggingface dataset:
assembling the joiner oligo with the first digested nucleic acid and the second nucleic acid. 
sastavljanje spojnog oligonukleotida sa prvom digestiranom nukleinskom kiselinom i drugom digestiranom nukleinskom kiselinom, pri čemu se sastavljanjem rekonstituiše završni dio.
ligating the joiner oligo to the first digested nucleic acid and the second nucleic acid. 
povezivanje spojnog oligonukleotida sa prvom digestiranom nukleinskom kiselinom i drugom digestiranom nukleinskom kiselinom.
A washing machine for washing planar textile products, the washing machine (1) comprising: 
Plosnati stroj za pranje, za pranje plosnatih tekstilnih proizvoda, pri čemu plosnati stroj (1) za pranje sadrži:
An immunogenic composition comprising the variant SpA of any one of claims 1 to 8. An immunogenic composition according to claim 9, further comprising at least a second staphylococcal antigen, wherein the second staphylococcal antigen is optionally selected from the group consisting of ClfA, EsaB, Emp, EsxA, EsxB, EsaC, Eap, Ebh, Coa, vWh, Hla, SdrC, SdrE, IsdA, IsdB, IsdC, ClfB, SasF peptide, a type V and/or a type VIII capsular polysaccharide or oligosaccharide from S. aureus. 
Imunogeni pripravak koji obuhvaća imunogenu varijantu SpA prema bilo kojem patentnom zahtjevu od 1 do 8, opcionalno obuhvaća najmanje drugi stafilokokni antigen, naznačen time, što je drugi stafilokokni antigen opcionalno odabran iz skupine koja se sastoji od ClfA, EsaB, Emp, EsxA, EsxB, EsaC, Eap, Ebh, Coa, vWh, Hla, SdrC, SdrE, IsdA, IsdB, IsdC, ClfB, SasF peptida, kapsularnog polisaharida tipa V i/ili tipa VII ili oligosaharida iz bakterije S. aureus.
The shelf according to claim 12, having a length in a range from 1250 to 1350 mm and a width in a range from 530 to 570 mm. 
Polica (10) sukladno patentnom zahtjevu 10, ima dužinu u opsegu od 1250 do 1350 mm i širinu u opsegu od 530 do 570 mm.
An apparatus for testing a multifunction and a drug response of a platelet based on a centrifugal microfluidics comprising: 
Uređaj za ispitivanje multifunkcije funkcije i reakcije na lijek trombocita na temelju centrifugalne mikrofluidike obuhvaća:
The apparatus according to Claim 7, wherein the P2Y12 receptor antagonist is at least one chosen from clopidogrel, ticlopidine, prasugrel, AR-C67085MX, cangrelor, C1330-7, MRS 2395 and 2-methylthioadenosine-5'-monophosphate. 
Uređaj sukladno patentnom zahtjevu 4, pri čemu je antagonist receptora P2Y12 najmanje jedan odabran između klopidogrela, tiklopidina, prasugrela, AR-C67085MX, kangrelora, C1330-7, MRS 2395 i 2- metiltioadenozin-5’-monofosfata.
The apparatus according to Claim 3, wherein a minimum shear rate in the shear flow generated by the stirrer is at least 5,000 (s-1) or a minimum shear stress is at least 8 Pa. 
Uređaj sukladno patentnom zahtjevu 1, pri čemu je miješalica (32) prilagođena proizvesti minimalnu pomičnu brzinu u pomičnom protoku od najmanje 5.000 (s-1) ili minimalno pomično naprezanje od najmanje 8 Pa.
The apparatus according to Claim 1, wherein a microfluidic valve is installed in the front part of the microchannel to control the flow of the blood sample. 
Uređaj sukladno patentnom zahtjevu 1, pri čemu je mikrofluidni ventil (42) instaliran u prednjem dijelu mikrokanala (40) da bi se kontrolirao protok uzorka krvi.
The apparatus according to Claim 1, wherein the microchannel is shaped in the form of at least one of a straight line, a curve or a zigzag, or the combination thereof. 
Uređaj sukladno patentnom zahtjevu 1, pri čemu je mikrokanal (40) u obliku najmanje jedne ravne linije, krivulje ili cik-cak linije, ili kombinacije navedenih.
The apparatus according to Claim 1, wherein a plurality of the intermediate chambers are formed at a plurality of points in the straight channel. 
Uređaj sukladno patentnom zahtjevu 1, pri čemu se više međukomora formira na više točaka u ravnom kanalu.
the base is triethylamine; and the solvent is tetrahydrofuran. 
baza je trimetilamin; i otapalo je tetrahidrofuran.
A nucleic acid, encoding a peptide according to any one of claims 1, 3 or 4, or an expression vector capable of expressing said nucleic acid. 
Nukleinska kiselina koja kodira peptid u skladu s bilo kojim od patentnih zahtjeva 1, 3 ili 4, ili ekspresijski vektor koji može eksprimirati navedenu nukleinsku kiselinu.
a pharmaceutical composition comprising: calcifediol, 
farmaceutski sastav koji sadrži: kalcifediol,
an oily component selected from the group consisting of a medium chain triglyceride, isopropyl myristate, a C14-C18 alkyl alcohol, a C14-C18 alkenyl alcohol, lanolin alcohol and mixtures thereof, and 
uljnu komponentu izabranu iz grupe koja se sastoji od triglicerida srednjeg lanca, izopropil miristrata, C14-C18 alkil alkohola, C14-C18 alkenil alkohola, lanolin alkohola i njihovih smjesa, i
a pharmaceutically acceptable organic solvent selected from the group consisting of ethanol, isopropanol, propylene glycol, polyethylene glycol, benzyl alcohol and mixtures thereof; wherein the soft capsule shell encapsulates the pharmaceutical composition and wherein said pharmaceutical composition is devoid of waxes. 
farmaceutski prihvatljivo organsko otapalo izabrano iz grupe koja se sastoji od etanola, izopropanola, propilen glikola, polietilen glikola, benzil alkohola i njihovih smjesa, pri čemu omotač meke kapsule inkapsulira farmaceutski sastav i gdje spomenuti farmaceutski sastav je lišen voska.
Soft capsule according to any one of the preceding claims, wherein the oily component is selected from the group consisting of a medium chain triglyceride, isopropyl myristate, a C14-C18 alkenyl alcohol, and mixtures thereof. 
Meka kapsula prema bilo kojem od prethodnih zahtjeva, gdje je uljna komponenta izabrana iz grupe koja se sastoji od triglicerida srednjeg lanca, izopropil miristrata, C14-C18 alkenil alkohola, i njihovih smjesa.
Soft capsule according to any one of the preceding claims, wherein the pharmaceutical composition further comprises a bisphosphonate. 
Meka kapsula prema bilo kojem od prethodnih zahtjeva, pri čemu farmaceutski sastav dalje sadrži bisfosfonat.
Soft capsule for use according to claim 14, wherein the soft capsule is for administration once every three months, once every two months, once a month, once every three weeks, once every two weeks, once a week, or once a day. 
Meka kapsula za upotrebu prema zahtjevu 12, pri čemu je meka kapsula za primjenu jednom svaka tri mjeseca, jednom svaka dva mjeseca, jednom mjesečno, jednom svaka tri tjedna, jednom svaka dva tjedna, jednom tjedno, ili jednom dnevno.
filling the shell with the mixture of step a), and 
punjenje omotača sa smjesom iz koraka a), i
drying the capsule obtained in step d). 
sušenje kapsule dobivene u koraku d).
The apparatus according to claim 1, wherein the second angle of each of the plurality of paddles is one of 0°, 45°, 90°, 135°, and 180°. 
Uređaj prema patentnom zahtjevu 1, naznačen time, da se drugi kut lopatice (118) svakog od većeg broja krakova za miješanje (116), pruža slijedom uzastopno od 0, 45, 90, 135 stupnjeva do 180 stupnjeva.
micro-organisms, Bifidobacterium sp. 
mikroorganizama, Bifidobacterium sp.
micro-organisms, Lactobacillus sp. 
mikroorganizama, Lactobacillus sp.
hypotaurine at a concentration of at least about 0.0001 mM; 
u koncentraciji od najmanje oko 0.0001 mM; ili
additionally contains a buffer; and/or 
dodatno sadrži međuspremnik; i / ili
The composition according to any of claims 6 to 9, which is selected from the group consisting of syrups, drops, solutions, dispersions, suspensions and emulsions. 
Pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time što je izabran iz skupine koja se sastoji od sirupa, kapi, otopina, disperzija, suspenzija i emulzija.
The ophthalmic aqueous solution according to claim 1, wherein the PGF2a analogue is latanoprost. 
Oftalmološka vodena otopina prema zahtjevu 1, gdje je spremnik jedinična doza ili jedinično dozni spremnik.
Eur. B or both. 
Eur. B ili oboje.
administering said composition to the eye of the mammal repeatedly for an extend period of time, preferably wherein the composition is administered at least once a day for a period of at least one month. 
davanje navedenog pripravka u oko sisavca opetovano tijekom duljeg vremenskog razdoblja, pri čemu se poželjno pripravak primjenjuje najmanje jednom dnevno tijekom perioda od najmanje jednog mjeseca.
The composition for use in a method as in claim 16, the method further comprising, prior to administering, diagnosing the eye of the mammal with an eye disorder that is suitably treated with chronic administration of a therapeutic agent, preferably wherein the eye disorder is elevated intraocular pressure. 
Pripravak za upotrebu u postupku prema patentnom zahtjevu 14, naznačen time, da postupak nadalje sadrži, prije primjene, dijagnosticiranje oka sisavca s poremećajem oka koji je prikladno tretiran s kroničnim davanjem terapeutskog sredstva, gdje je poželjno poremećaj oka povišen intraokularni tlak.
A respiratory syncytial virus (RSV) fusion (F) protein comprising: 
Respiratorni sincicijski virus (RSV) fuzijski (F) protein koji sadrži:
A compound that has the structure: 
Spoj koji ima strukturu:
The pharmaceutical composition of claim 2, further comprising a pharmaceutically acceptable carrier. 
Farmaceutski pripravak sukladno patentnom zahtjevu 2, nadalje sadrži farmaceutski prihvatljiv nosač.
The cell according to claim 6 for use in the treatment of cancer. The peptide for use according to claims 1, 3 or 4, the cell for use according to claim 10, wherein said cancer is selected from astrocytoma, pilocytic astrocytoma, mixed gliomas, ependymal cell tumors, gangliogliomas, gangliocytoma, glioblastoma, medulloblastoma, neuroblastoma, astroblastoma, germinoma, oligodendrogliomas, primitive neuroectodermal tumors, dysembryoplastic neuroepithelial tumor, neuroepithelial tumors of uncertain origin, choroid plexus tumors, gliomatosis cerebri, ependymoma, ependymoblastoma, retinoblastoma, and teratoma. 
Lijek koji se sastoji od peptida za upotrebu u skladu s patentnim zahtjevom 1, ili CTL za upotrebu u skladu s patentnim zahtjevom 3, skupa s prikladnim nosačem, za upotrebu u liječenju karcinoma, pri čemu je navedeni karcinom odabran iz sljedećeg: astrocitom, pilocitični astrocitom, miješani gliomi, tumori ependimalnih stanica, gangliogliomi, gangliocitom, glioblastom, meduloblastom, neuroblastom, astroblastom, germinoma, oligodendroglioma, primitivni neuroektodermalni tumori, disembrioplastičan neuroepitelijalni tumor, neuroepitelijalni tumori nepoznatog podrijetla, tumori koroidnog pleksusa, gliomatosis cerebri, ependimom, ependimoblastom, retinoblastom i teratom.
subjecting said affinity chromatography sample to a reduction in pH thus forming a reduced pH sample, wherein said reduced pH sample has a pH of about 3 to about 4; 
podvrgavanje navedenog afinitetnog kromatografskog uzorka redukciji u pH na taj način formirajući uzorak s reduciranim pH, pri čemu navedeni uzorak s reduciranim pH ima pH od oko 3 do oko 4;
The method of claim 1, wherein said reduction in pH in step (b) is accomplished by admixing a suitable acid with said sample mixture, and wherein said suitable acid is selected from the group consisting of citric acid, acetic acid, and caprylic acid. 
Postupak sukladno patentnom zahtjevu 1, naznačen time što navedena redukcija u pH u koraku (c) je postignuta miješanjem odgovarajuće kiseline s navedenom mješavinom uzorka, izborno pri čemu navedena odgovarajuća kiselina je odabrana iz skupine sastavljene od limunske kiseline, octene kiseline i kaprilne kiseline.
The method of claim 1, wherein said HIC material is: 
Postupak sukladno patentnom zahtjevu 1, naznačen time što navedeni HIC materijal je:
a HIC resin having a stationary phase comprising hydrophobic groups, or 
HIC kolona čija stacionarna faza sadrži hidrofobne skupine, ili
an agarose resin substituted with phenyl groups. 
agarozna smola supstituirana s fenil skupinom.
The method of claim 1 further comprising a filtration step, wherein said HIC sample is subjected to filtration to remove viral particles and to facilitate buffer exchange. 
Postupak sukladno patentnom zahtjevu 1 koji dodatno sadrži korak filtriranja, pri čemu navedeni uzorak HIC je podvrgnut filtriranju da bi se uklonile virusne čestice i da bi se olakšala razmjena pufera.
The method for preparing a pharmaceutical composition according to claim 3 or 5, wherein the organic solvent is present in an amount of 20-100 wt%, preferably 50-95 wt%, and more preferably 50-80 wt%, relative to the total weight of the wetting agent. 
Postupak dobivanja farmaceutskog pripravka sukladno patentnom zahtjevu 1 ili 4, pri čemu je organsko otapalo prisutno u količini od 20-100 tež.%, poželjno 50-95 tež.%, i još poželjnije 50-80 tež.%, u odnosu na ukupnu težinu pripravka za ovlaživanje.
The method for preparing a pharmaceutical composition according to claim 1, wherein the active ingredient is present in an amount of 5%-70%, preferably 10%-50%, and more preferably 20-40% by weight, relative to the total weight of the composition. 
Postupak dobivanja farmaceutskog pripravka sukladno patentnom zahtjevu 1, pri čemu je aktivni sastojak prisutan u količini od 5%-70%, poželjno 10%-50%, i još poželjnije 20-40% težine, u odnosu na ukupnu težinu pripravka.
The method for preparing a pharmaceutical composition according to claim 1, wherein the pharmacologically acceptable salt is maleate salt, and preferably dimaleate salt. 
Postupak dobivanja farmaceutskog pripravka sukladno patentnom zahtjevu 1, pri čemu je farmaceutski prihvatljiva sol, sol maleata, i poželjno sol dimaleata.
The method for preparing a pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition comprises a filler, wherein the filler is preferably one or more of microcrystalline cellulose, calcium hydrogen phosphate, mannitol, pregelatinized starch and lactose, and the filler is preferably present in an amount of 5-80% by weight, relative to the total weight of the composition. 
Postupak dobivanja farmaceutskog pripravka sukladno patentnom zahtjevu 1, naznačen time što taj farmaceutski pripravak sadrži punilo, pri čemu je to punilo poželjno jedan pripravak ili više od mikrokristalne celuloze, kalcij hidrogen fosfata, manitol, prethodno želatinizirani škrob i laktoza, i punilo je poželjno prisutno u količini od 5-80% težine, u odnosu na ukupnu težinu pripravka.
The method for preparing a pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition comprises a binder, wherein the binder is preferably one or more of hydroxypropyl methyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone and methyl cellulose, and the binder is preferably present in an amount of 0.5-15% by weight, relative to the total weight of the composition. 
Postupak dobivanja farmaceutskog pripravka sukladno patentnom zahtjevu 1, naznačen time što farmaceutski pripravak sadrži vezivno sredstvo, pri čemu je vezivno sredstvo preporučljivo jedna ili više od hidroksipropil metil celuloze, hidroksipropil celuloze, natrij karboksimetil celuloze, polivinilpirolidona i metil celuloze, i vezivno sredstvo je poželjno prisutno u količini od 0,5-15% težine, u odnosu na ukupnu težinu pripravka.
The method for preparing a pharmaceutical composition according to claim 1, characterized in that the pharmaceutical composition comprises a disintegrant, wherein the disintegrant can be one or more selected from the group consisting of low-substituted hydroxypropyl cellulose, croscarmellose sodium, sodium carboxymethyl starch and cross-linked polyvinylpyrrolidone, and the disintegrant is preferably present in an amount of 2-20%, preferably 4-15%, and more preferably 6-10% by weight, relative to the total weight of the composition. 
Postupak dobivanja farmaceutskog pripravka sukladno patentnom zahtjevu 1, naznačen time što farmaceutski pripravak sadrži sredstvo za razgradnju, pri čemu to sredstvo za razgradnju može biti jedno ili više odabranih iz skupine sastavljene od slabo-supstituirane hidroksipropil celuloze, natrij kroskarmeloze, natrij karboksimetil škroba i umreženog polivinilpirolidona, i sredstvo za razgradnju je poželjno prisutno u količini od 2-20%, poželjno 4-15%, i još poželjnije 6-10% težine, u odnosu na ukupnu težinu pripravka.
2-20 wt% of a disintegrant, wherein the disintegrant is cross-linked polyvinylpyrrolidone; 
2-20 tež.% sredstva za razgradnju, pri čemu je sredstvo za razgradnju umreženi polivinilpirolidon;
0.5-15 wt% of a binder, wherein the binder is one or more selected from the group consisting of polyvinylpyrrolidone, hydroxypropyl methyl cellulose and hydroxypropyl cellulose; and 
0,5-15 tež.% vezivnog sredstva, pri čemu je vezivno sredstvo jedno ili više odabran iz skupine sastavljene od polivinilpirolidona, hidroksipropil metil celuloze i hidroksipropil celuloze; i
Use of the pharmaceutical composition according to claim 15 in the preparation of a medicament for treating cancer, preferably gastric cancer, lung cancer or breast cancer. 
Farmaceutski pripravak sukladno patentnom zahtjevu 14 za upotrebu u liječenju karcinoma, poželjno karcinoma želuca, karcinoma pluća, ili karcinoma dojke.
is selected from the substituted or unsubstituted group consisting of C1-4 alkyl or C3-4 cycloalkyl, and its substituents are selected from the group consisting of deuterium, halogen, C1-2 alkyl or C3-4 cycloalkyl; 
se bira između supstituirane ili nesupstituirane C1-4 alkilne skupine i supstituiranog ili nesupstituiranog C3-4 cikloalkila, a njegove supstituente se bira iz skupine koju čine deuterij, halogen, C1-2 alkil i C3-4 cikloalkil;
A pharmaceutical acceptable composition comprising the compound of claim 1 or its pharmaceutically acceptable salt as active ingredient, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili njegovu farmaceutski prihvatljivu sol, kao aktivni sastojak ili glavni aktivni sastojak, kao i farmaceutski prihvatljivi nosač.
each R14 is independently selected from a halogen atom, oxo, cyano, nitro, C1-4 alkyl optionally substituted with one or more halogen atoms, C1-4 alkoxy optionally substituted with one or more halogen atoms, (C1-6 alkoxy)carbonyl, a group -NR27R28, a group -SO2NR35R36, C1-4 alkylthio, and 5- to 10-membered heterocycloalkyl; 
svaki R14 je neovisno odabran od halogenog atoma, okso, cijano, nitro, C1-4 alkila po izboru supstituiranog s jednim ili više halogenih atoma, C1-4 alkoksi po izboru supstituiranog s jednim ili više halogenih atoma, (C1-6 alkoksi)karbonila, skupine -NR27R28, skupine -SO2NR35R36, C1-4 alkiltio, i 5- do 10-članog heterocikloalkila;
is C1-8 alkyl substituted with one or more hydroxy groups, or R43 and R44 together with the nitrogen atom to which they are attached may form morpholino; 
je C1-8 alkil supstituiran s jednom ili više hidroksi skupina, ili i R44 zajedno s dušikovim atomom na koji su oni vezani mogu tvoriti morfolino;
is C1-8 alkyl substituted with one or more hydroxy groups; 
je C1-8 alkil supstituiran s jednom ili više hidroksi skupina;
is -(CH2)z-NR60R61 (z is an integer selected from 1 to 4, R60 is a hydrogen atom or C1-4 alkyl, and R61 is (C1-3 alkoxy)C1-4 alkyl, or R60 and R61 together with the nitrogen atom to which they are attached may form morpholino); 
je -(CH2)z-NR60R61 (z je cijeli broj koji se bira od 1 do 4, R60 je vodikov atom ili C1-4 alkil, i R61 je (C1-3 alkoksi)C1-4 alkil, ili R60 i R61 zajedno s dušikovim atomom na koji su oni vezani mogu tvoriti morfolino);
is a hydrogen atom or C1-3 alkyl; and R59 is C1-8 alkyl substituted with one or more hydroxy groups. 
je vodikov atom ili C1-3 alkil; i je C1-8 alkil supstituiran s jednom ili više hidroksi skupina.
is carboxy, 3- to 6-membered heterocycloalkyl, C1-4 alkoxy optionally substituted with one or more hydroxy groups, or a group -(O(CH2)o)p-OH; 
je karboksi, 3- do 6-člani heterocikloalkil, C1-6 alkoksi po izboru supstituiran s jednom ili više hidroksi skupina, ili skupina -(O(CH2)o)p-OH;
each R12 is independently selected from a halogen atom, hydroxy, C1-6 alkoxy optionally substituted with one or more hydroxy groups, (C1-3 alkoxy)carbonyl, 3- to 6-membered heterocycloalkyl, 5- or 6-membered heteroaryl, and a group -NR39R40; 
svaki R12 je neovisno odabran od halogenog atoma, hidroksi, C1-6 alkoksi po izboru supstituiranog s jednom ili više hidroksi skupina, (C1-3 alkoksi)karbonila, 3- do 6-članog heterocikloalkila, 5- ili 6-članog heteroarila, i skupine -NR39R40;
Rj is a halogen atom; and Rk is hydroxy, C2-6 alkynyl optionally substituted with a substituent R11, or C1-6 alkoxy optionally substituted with a substituent R12. 
Rj je halogeni atom; i Rk je hidroksi, C2-6 alkinil po izboru supstituiran sa supstituentom R11, ili C1-6 alkoksi po izboru supstituiran sa supstituentom R12.
The compound according to any one of claims 1 to 27 or the salt thereof, or the solvate of the compound or the salt for use in the prevention and/or treatment of a disease selected from hyperphosphatemia, secondary hyperparathyroidism, and chronic renal failure. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 28 ili njegova sol, ili solvat spoja ili sol naznačen time što je za uporabu za sprječavanje i/ili liječenje bolesti odabrane od hiperfosfatemije, sekundarnog hiperparatireoidizma i kroničnog zatajenja bubrega.
The compound according to any of the preceding claims selected from the following group of compounds: 
Spoj, naznačen time, da je odabran iz sljedeće skupine spojeva:
a cyclohexyl group substituted by one hydroxy group, or 
skupina cikloheksil supstituirana s jednom hidroksi skupinom, ili
a tetrahydropyranyl group substituted by one hydroxy group; 
skupina tetrahidropiranil supstituirana s jednom hidroksi skupinom;
An anti-OX40 antibody which comprises (i) a VH chain comprising three CDRs; and (ii) a VL chain comprising three CDRs, wherein: 
Protutijelo protiv OX40, naznačeno time što sadrži (i) VH lanac koji ima tri CDR-a; i (ii) VL lanac koji ima tri CDR-a, gdje:
determining allele frequencies of the mapped DNA segment sequences for at least one of the designated polymorphisms; 
određivanje učestalosti alela mapiranih sekvenci DNK segmenta za najmanje jedan od naznačenih polimorfizama;
wherein classifying the at least one designated polymorphism comprises applying a threshold to the allele frequency determined in (d); 
pri čemu razvrstavanje najmanje jednog naznačenog polimorfizma obuhvaća primjenu praga na učestalost alela određenu u (d);
wherein classifying the at least one designated polymorphism comprises applying the allele frequency data from (d), obtained for a plurality of polymorphisms, to a mixture model, optionally wherein the mixture model employs factorial moments; 
pri čemu razvrstavanje najmanje jednog naznačenog polimorfizma obuhvaća primjenu podataka o učestalosti alela iz (d), dobivenih za mnoštvo polimorfizama, u model distribucije u smjesi, opcionalno gdje model distribucije u smjesi koristi faktorske trenutke;
wherein the DNA obtained from a bodily fluid of a pregnant individual is cell-free DNA obtained from the plasma of the pregnant individual; 
pri čemu DNK dobivena iz tjelesne tekućine trudne osobe predstavlja DNK oslobođenu od stanica, dobivenu iz plazme trudne osobe;
wherein mapping the DNA segments obtained from the blood of the individual carrying the fetus comprises computationally mapping said segments to a database of polymorphisms; 
pri čemu mapiranje DNK segmenata, dobivenih iz krvi osobe koja nosi fetus, obuhvaća računalno mapiranje navedenih segmenata u okviru baze podataka polimorfizama;
further comprising, based on the estimate of the fraction of fetal DNA, prescribing, initiating, and/or altering treatment of a human subject from whom the maternal test sample was taken; 
dodatno obuhvaća, zasnovano na procjeni frakcije fetalne DNK, propisivanje, započinjanje i/ili izmjenu liječenja ljudskog subjekta iz koga je uzet uzorak majke za ispitivanje;